@article{67d2b0bc504448018aaa1cafa03d9f5c,
title = "The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali,Indonesia",
abstract = "COVID-19 is a major public health problem, with still questionable specific cure. Favipiravir is a COVID-19 antiviral that is potentially a therapy for COVID-19. This study aimed to analyze its effectivity and safety in moderate to critical hospitalized patients. This study was a retrospective cohort in a tertiary referral hospital in Denpasar City, Bali Province, Indonesia, from August 2020 to January 2021. There was a total of 192 patients; 96 in the favipiravir group and 96 in the non-favipiravir group (remdesivir/oseltamivir). Effectivity was measured by assessing the clinical condition at the end of the isolation period of 14 days. The favipiravir group showed better clinical conditions than the non-favipiravir group (79.2% vs. 56.3%; adjusted RR = 2.196; 95% CI = 1.084 - 4.451; p-value = 0.029), seen from being free of fever and respiratory problems. Stratification analysis demonstrated that the clinical improvement was significantly different in the severe/critical group in favor of favipiravir (RR = 1.573; 95% CI = 1.139-2.172). The most common non-serious adverse events (AE) found in the use of favipiravir were gastrointestinal disturbances (12.5%). In brief, favipiravir is effective in severe/critical cases, and less serious AE were found in its use. Appropriate treatment is expected to help in reducing the public health burden. ",
keywords = "COVID-19, Effectivity, Favipiravir, Safety",
author = "Herni Damayanti and Sajinadiyasa, {I. Gede K.} and Risni, {Hindun Wilda} and Rani Sauriasari",
note = "Funding Information: The abstract of this paper has been presented in the 16th APRU Multi-Hazards Symposium 2021 hosted by Disaster Risk Reduction Center Universitas Indonesia in collaboration with the Association of Pacific Rim Universities. The authors are grateful to National Agency for Research and Innovation of the Republic of Indonesia for giving financial support through PDUPT Grant No. NKB-064/UN2.RST/HKP.05.00/2021. The authors also thank the pharmacy division and medical record division at Sanglah General Hospital for the valuable support. Funding Information: The abstract of this paper has been presented in the 16th APRU Multi-Hazards Symposium 2021 hosted by Disaster Risk Reduction Center Universitas Indonesia in collaboration with the Association of Pacific Rim Universities. The authors are grateful to National Agency for Research and Innovation of the Republic of Indonesia for giving financial support through PDUPT Grant No. NKB-064/UN2.RST/HKP.05.00/2021. The authors also thank the pharmacydivision and medical record division at Sanglah General Hospital for the valuable support. Publisher Copyright: Copyright @ 2021.",
year = "2021",
month = nov,
doi = "10.21109/kesmas.v16i4.5433",
language = "English",
volume = "16",
pages = "289--297",
journal = "Kesmas: Jurnal Kesehatan Masyarakat Nasional",
issn = "2460-0601",
publisher = "Universitas Indonesia, Faculty of public health",
number = "4",
}